Education
About Us
Working with TipRanks
Follow Us
Christopher Hite Insider Profile
4 Followers
Christopher Hite, Director at Acceleron Pharma, holds 722.34K shares in Royalty Pharma (Ticker: RPRX), holds 0.00 shares in Acceleron Pharma (Ticker: XLRN).
Christopher Hite Acceleron Pharma (XLRN)Director
Acceleron Pharma (XLRN)
Director
Not Ranked
Christopher Hite has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Christopher Hite's holdings
Insider Roles
EVP & Vice Chairman
Roles that Christopher Hite holds in companies
Most Profitable Insider Trade
The most profitable trade made by Christopher Hite
Christopher Hite's Trading History
Acceleron Pharma
Nov 22, 2021
―
Uninformative Sell
―
$0.00
Royalty Pharma
Aug 08, 2025
EVP & Vice Chairman
Uninformative Buy
―
$26.26M
List of latest transactions for each holding click on a transaction to see Christopher Hite's performance on stock
You May Also Like
Christopher Hite insider profile FAQ
What is the percentage of profitable transactions made by Christopher Hite?
The percentage of profitable transactions made by Christopher Hite is ―.
What is the average return per transaction made by Christopher Hite?
The average return per transaction made by Christopher Hite is ―.
What stocks does Christopher Hite hold?
Christopher Hite holds: XLRN, RPRX stocks.
What was Christopher Hite’s latest transaction?
Christopher Hite latest transaction was an Uninformative Buy of ―.
What was Christopher Hite's most profitable transaction?
Christopher Hite’s most profitable transaction was an Informative Buy of RPRX stock on June 23, 2020. The return on the trade was -15.90%.
What is Christopher Hite's role in Acceleron Pharma?
Christopher Hite's role in Acceleron Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.